Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

All NewsMay 15, 2026

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT